Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2024 Annual Meeting | Industry Therapeutic Update from argenx: Our Evolving Understanding of CIDP: Pathophysiology, Current Unmet Treatment Needs, and the Rationale for Targeting FcRn

Tuesday 04/16/24
06:00 PM - 08:00 PM MDT Add To Calendar
Hyatt Regency | Centennial F-G
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Richard Lewis, Christyn Marie Edmundson, MD
General Neurology
Join us for a discussion of the underlying immune mechanisms in chronic inflammatory demyelinating polyneuropathy (CIDP). Learn about ongoing efforts to inhibit IgG recycling for the potential treatment of adult patients with CIDP.


Provide an overview of CIDP, current understanding of pathophysiology, and unmet needs for treatments
Understand the rationale for targeting FcRn in CIDP


This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials

Event Timeline
06:00 PM - 07:00 PM MDT Speaker Industry Therapeutic Update from argenx: Our Evolving Understanding of CIDP: Pathophysiology, Current Unmet Treatment Needs, and the Rationale for Targeting FcRn
Faculty Disclosures
Richard Lewis No disclosure on file
Christyn Marie Edmundson, MD Dr. Edmundson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion . Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Edmundson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam. Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB.